top of page
Pre-Selection of patients who would respond to combination of chemotherapy and low dose immunotherapy using human histoculture platform
The Farcast TruTumor platform provides the unique opportunity to identify patients who would truly benefit from treatment with chemotherapy (CT) + Low Dose Nivolumab (LDN) in combination. Furthermore, TruTumor response prediction showed 100% concordance with an observational trial where patients were treated with CT+LDN.
Enter your details to see the full poster now
bottom of page